Delcath Systems, Inc. Expands Phase III Trial for Metastatic Melanoma to Include John Wayne Cancer Institute in California
Published: Aug 12, 2008
NEW YORK, NY--(Marketwire - August 12, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the John Wayne Cancer Institute ("JWCI"), at Saint John's Health Center in Santa Monica, California, has joined Delcath's Phase III clinical trial for the treatment of metastatic melanoma in the liver. JWCI is the eighth center in this multi-center trial testing the Company's Percutaneous Hepatic Perfusion (PHP) System for the isolated, high-dose delivery of the anti-cancer agent melphalan.